Home > > Pharmaceuticals And Healthcare > > ACE Inhibitors Market Size, Share, Trends And Forecast 2024 - 2031
Id: CBI_1544 | Pages: 333 | Format : PDF | Published : | Author : Amit Sati | Category : Pharmaceuticals And Healthcare
ACE Inhibitors market size is estimated to reach over USD 9.78 Billion by 2031 from a value of USD 6.70 Billion in 2023 and is projected to grow by USD 6.91 Billion in 2024, growing at a CAGR of 4.8% from 2024 to 2031.
ACE inhibitors, or angiotensin-converting enzyme inhibitors, are a class of medications primarily used to treat high blood pressure, heart failure, and certain kidney diseases. These medications work by blocking the enzyme that produces angiotensin II, a substance that narrows blood vessels, leading to increased blood pressure. By inhibiting this enzyme, ACE inhibitors help relax blood vessels, reduce blood pressure, and improve the efficiency of the heart. They are commonly prescribed for patients with cardiovascular conditions and are known to reduce the risk of strokes, heart attacks, and other complications related to hypertension. The healthcare sector, particularly hospitals and clinics, relies on these medications to manage chronic conditions effectively. End-use industries such as pharmaceuticals and healthcare providers are key drivers of the market, with ongoing research aimed at improving the efficacy and safety of these medications.
The growing global prevalence of hypertension and cardiovascular diseases is a key driver of the ACE inhibitors market growth. ACE inhibitors, which work by relaxing blood vessels and reducing blood pressure, are widely prescribed for the treatment of hypertension, heart failure, and chronic kidney diseases. With the increasing incidence of lifestyle-related diseases such as obesity, diabetes, and high cholesterol, the demand is expanding, particularly in developed regions like North America and Europe where the aging population is more susceptible to these conditions. Additionally, the global shift toward preventive healthcare and early intervention strategies is further driving the use of these inhibitors in managing high blood pressure and reducing the risk of severe cardiovascular events such as heart attacks and strokes.
One of the primary restraints in the market is the growing competition from alternative treatments, including angiotensin II receptor blockers (ARBs) and direct renin inhibitors, which offer similar therapeutic benefits but with fewer side effects. ACE inhibitors are associated with adverse effects such as cough, hyperkalemia, and angioedema, which can limit patient adherence and lead to treatment discontinuation. Moreover, the introduction of newer therapies with improved safety profiles, such as ARBs, is causing a gradual shift in prescribing patterns among healthcare providers. The increasing preference for these alternatives, especially in patients who experience significant side effects with these inhibitors, is hindering the ACE inhibitors market growth.
Emerging markets in Asia-Pacific, Latin America, and the Middle East present significant ACE inhibitors market opportunities. The rising incidence of hypertension in these regions, driven by urbanization, changing lifestyles, and growing healthcare awareness, is increasing the demand for affordable and effective treatments. Moreover, the development of combination therapies, where these inhibitors are paired with other antihypertensive agents such as diuretics or calcium channel blockers, is gaining traction as it offers enhanced efficacy with improved patient compliance. These combination therapies are particularly valuable in managing comorbid conditions in patients with multiple cardiovascular risk factors, creating a broader scope for market expansion.
Based on drug type, the market is segmented into captopril, enalapril, lisinopril, ramipril, fosinopril, quinapril, benazepril, and others.
The lisinopril segment accounted for the largest revenue of the total ACE inhibitors market share in 2023.
The ramipril segment is anticipated to register the fastest CAGR during the forecast period.
Based on application, the market is segmented into hypertension, congestive heart failure (CHF), chronic kidney disorders, cardiovascular diseases (CVDs), and others.
The hypertension segment accounted for the largest revenue share of 45.15% in 2023.
The chronic kidney disorders (CKD) segment is anticipated to register the fastest CAGR during the forecast period.
Based on route of administration, the market is segmented into oral and intravenous.
The oral segment accounted for the largest revenue of the overall ACE inhibitors market share in 2023.
The intravenous segment is anticipated to register the fastest CAGR during the forecast period.
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the largest revenue share in 2023.
The online pharmacies segment is anticipated to register the fastest CAGR during the forecast period.
The regions covered are North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.
Asia Pacific region was valued at USD 1.36 Billion in 2023. Moreover, it is projected to grow by USD 1.42 Billion in 2024 and reach over USD 2.24 Billion by 2031. Out of this, China accounted for 36% of the total market share. Asia-Pacific is the fastest-growing region for the market, with countries like China, India, and Japan leading due to their large populations and rising incidence of cardiovascular diseases. Rapid urbanization, changes in lifestyle, and increasing rates of obesity and diabetes have contributed to the surge in hypertension cases, driving demand. Growing healthcare investments and expanding access to pharmaceuticals in these countries also propel market growth. However, lack of awareness and limited healthcare infrastructure in rural areas remain significant challenges.
North America is estimated to reach over USD 4.08 Billion by 2031 from a value of USD 2.75 Billion in 2023 and is projected to grow by USD 2.84 Billion in 2024. North America holds the largest share of the market, driven by the high prevalence of hypertension and cardiovascular diseases, especially in the U.S. The region benefits from a well-established healthcare infrastructure and a large aging population, contributing to the demand for ACE inhibitors as a first-line treatment for hypertension. Additionally, the high awareness of cardiovascular health and the availability of advanced pharmaceuticals support market growth. However, rising healthcare costs and the increasing availability of generic alternatives may slow ACE inhibitors market expansion.
Europe is a key market, with countries like Germany, the UK, and France leading in the adoption of cardiovascular treatments. The high incidence of hypertension and related cardiovascular conditions, especially among the elderly population, drives demand in the region. Governments and healthcare systems in Europe focus heavily on preventive care and management of chronic diseases, which supports the market. However, stringent regulations and the growing preference for alternative therapies such as angiotensin receptor blockers (ARBs) may limit growth.
The Middle East & Africa region is seeing steady growth in the market, particularly in countries like Saudi Arabia, the UAE, and South Africa. Rising rates of hypertension and cardiovascular diseases due to changing lifestyles, coupled with government initiatives to improve healthcare access, are driving demand for ACE inhibitors. Saudi Arabia and the UAE have been focusing on cardiovascular health as part of broader healthcare reforms. However, limited access to advanced healthcare facilities and medications in some parts of Africa continues to hinder ACE inhibitors market potential.
Latin America is an emerging market, with Brazil and Mexico being the major contributors. The region's growth is driven by the increasing prevalence of cardiovascular diseases, partly due to rising obesity and diabetes rates. Governments in these countries are emphasizing preventive healthcare, which supports the demand for antihypertensive medications like ACE inhibitors. However, economic instability and limited healthcare budgets in some countries may slow market growth.
The ACE inhibitors market is highly competitive with major players providing products to the national and international markets. Key players are adopting several strategies in research and development (R&D), product innovation, and end-user launches to hold a strong position in the global ACE inhibitors market. Key players in the ACE Inhibitors industry include-
Approvals:
Product Launch:
Report Attributes | Report Details |
Study Timeline | 2018-2031 |
Market Size in 2031 | USD 9.78 Billion |
CAGR (2024-2031) | 4.8% |
By Drug Type |
|
By Application |
|
By Distribution Channel |
|
By Route of Administration |
|
By Region |
|
Key Players |
|
North America | U.S. Canada Mexico |
Europe | U.K. Germany France Spain Italy Russia Benelux Rest of Europe |
APAC | China South Korea Japan India Australia ASEAN Rest of Asia-Pacific |
Middle East and Africa | GCC Turkey South Africa Rest of MEA |
LATAM | Brazil Argentina Chile Rest of LATAM |
Report Coverage |
|
ACE Inhibitors market size is estimated to reach over USD 9.78 Billion by 2031 from a value of USD 6.70 Billion in 2023 and is projected to grow by USD 6.91 Billion in 2024, growing at a CAGR of 4.8% from 2024 to 2031.
ACE inhibitors are primarily used to treat hypertension (high blood pressure), heart failure, and chronic kidney diseases. They work by relaxing blood vessels, making it easier for the heart to pump blood, which helps reduce blood pressure and prevents heart-related complications.
North America is witnessing the highest demand for ACE inhibitors due to the high prevalence of cardiovascular diseases and hypertension, along with advanced healthcare infrastructure. The aging population in the U.S. and Canada also contributes to increased consumption of these medications.
One of the major challenges facing the ACE Inhibitors Market is the growing preference for alternative therapies such as angiotensin II receptor blockers (ARBs), which are considered to have fewer side effects. Additionally, the patent expirations of leading ACE inhibitors have increased the competition from generic drugs, impacting market revenue.